SANOFI CONS HEALTHC IND L SANOFICONR NSEPHARMA

Healthcare · Drug Manufacturers - General · India

https://www.sanofi.com/en/Consumer-Healthcare/health-and-well-being

Sanofi Consumer Healthcare India Limited operates as a fast-moving consumer healthcare company in India. It offers products in the allergy, physical wellness, and pain care segments under brands, such as Allegra, Combiflam, Avil, DePURA, Festal, and Novalgin NU through distributors, wholesalers, government institutions and hospitals, pharmacies, pharmacy chains, and e-commerce. The company was incorporated in 2023 and is based in Mumbai, India. Sanofi Consumer Healthcare India Limited is a subsidiary of Opella Healthcare Participations B.V.

Market & Price

Market Cap

₹10,582.68 Cr

Current Price

₹4,588.50

High / Low (52W)

₹5,696.00 / ₹3,999.50

Beta

Valuation

Stock P/E

40.98

Industry PE

37.60

Forward P/E

34.27

PEG Ratio

Book Value

₹166.71

Price to Book

27.52

P/S

11.32

EV/EBITDA

30.50

Dividend Yield

1.16%

Profitability & Returns

ROCE

76.99%

ROE

ROA

Profit Margin

27.58%

Op Margin

37.35%

EPS (Latest Qtr)

₹29.44

EPS (TTM)

₹111.96

Balance Sheet & Liquidity

Debt/Equity

0.06

Quick Ratio

Current Ratio

Debt

₹24.80 Cr

Total Assets

₹547.00 Cr

Current Assets

₹494.30 Cr

Working Capital

₹365.90 Cr

Ownership

Promoter Holding

71.46%

Chg in Prom Hold

FII / Inst Holding

17.77%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹10,216.87 Cr

Total Revenue (TTM)

₹935.00 Cr

EBITDA

₹334.98 Cr

Free Cash Flow

Operating Cash Flow

Shares Outstanding

₹2.30 Cr

Gross Margin

73.53%

Payout Ratio

49.10%

Growth (CAGR)

Revenue 5Y

27.04%

Profit 5Y

20.67%

Revenue (YoY)

32.80%

Earnings (YoY)

35.70%

PROS

Healthy ROCE of 77.0%.
Excellent profit margin of 27.6%.
Compounding revenue at 27.0% over 5 years.
Profit CAGR of 20.7% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SANOFICONR SANOFI CONS HEALTHC IND L NSEPHARMA	4,588.50	40.98	₹10,582.68 Cr	1.16%	76.99%	-	27.04%	20.67%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	172.60 Cr	220.90 Cr	233.90 Cr	251.00 Cr	229.20 Cr
Cost of Revenue	38.80 Cr	61.20 Cr	61.80 Cr	68.30 Cr	56.20 Cr
Gross Profit	133.80 Cr	159.70 Cr	172.10 Cr	182.70 Cr	173.00 Cr
Operating Expenses	71.80 Cr	92.50 Cr	90.40 Cr	96.30 Cr	87.40 Cr
Operating Income	62.00 Cr	67.20 Cr	81.70 Cr	86.40 Cr	85.60 Cr
EBITDA	69.20 Cr	82.40 Cr	88.00 Cr	94.40 Cr	94.40 Cr
Interest Expense	40.00 L	50.00 L	60.00 L	50.00 L	50.00 L
Pretax Income	66.80 Cr	78.90 Cr	84.10 Cr	90.50 Cr	90.70 Cr
Tax Provision	16.80 Cr	18.20 Cr	21.20 Cr	24.00 Cr	22.90 Cr
Net Income	50.00 Cr	60.70 Cr	62.90 Cr	66.50 Cr	67.80 Cr
Diluted EPS	21.69	26.36	27.31	28.87	29.44

Profit & Loss (Annual)

Figures in INR.

Metric	Dec 2023	Dec 2024	Dec 2025
Revenue	544.30 Cr	724.50 Cr	878.40 Cr
Cost of Revenue	194.00 Cr	186.10 Cr	230.10 Cr
Gross Profit	350.30 Cr	538.40 Cr	648.30 Cr
Operating Expenses	133.10 Cr	272.30 Cr	351.00 Cr
Operating Income	217.20 Cr	266.10 Cr	297.30 Cr
EBITDA	221.30 Cr	255.20 Cr	334.00 Cr
Interest Expense	20.00 L	3.90 Cr	2.00 Cr
Pretax Income	219.30 Cr	246.80 Cr	320.30 Cr
Tax Provision	54.40 Cr	65.80 Cr	80.20 Cr
Net Income	164.90 Cr	181.00 Cr	240.10 Cr
Diluted EPS	71.60	78.59	104.27

Compounded Sales Growth

5 Years:	27.04%
1 Year:	32.80%

Compounded Profit Growth

5 Years:	20.67%
1 Year:	35.70%

Stock Price Performance

1 Year:	-8.74%
6 Months:	-4.83%
3 Months:	+12.57%
1 Month:	-4.17%

Balance Sheet (Annual)

Figures in INR.

Metric	Dec 2023	Dec 2024	Dec 2025
Total Assets	345.40 Cr	431.30 Cr	547.00 Cr
Current Assets	335.20 Cr	391.70 Cr	494.30 Cr
Cash & Equivalents	1.60 Cr	326.90 Cr	374.80 Cr
Inventory	96.60 Cr	40.90 Cr	61.90 Cr
Receivables	31.60 Cr	13.70 Cr	29.60 Cr
Total Liabilities	137.80 Cr	158.30 Cr	163.00 Cr
Current Liabilities	129.90 Cr	130.60 Cr	128.40 Cr
Long Term Debt	-	-	-
Total Debt	0	20.30 Cr	24.80 Cr
Total Equity	207.60 Cr	273.00 Cr	384.00 Cr
Shares Outstanding	2.30 Cr	2.30 Cr	2.30 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-40.00 L	439.00 Cr	174.80 Cr
Investing Cash Flow	0	1.90 Cr	7.60 Cr
Financing Cash Flow	2.00 Cr	-115.60 Cr	-134.50 Cr
Capital Expenditure	-4.00 Cr	-9.90 Cr	-7.60 Cr
Free Cash Flow	-4.40 Cr	429.10 Cr	167.20 Cr
Net Change in Cash	1.60 Cr	325.30 Cr	47.90 Cr

Ratios (Annual)

Figures in %.

Metric	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	64.4%	74.3%	73.8%
Operating Margin %	39.9%	36.7%	33.8%
Net Margin %	30.3%	25.0%	27.3%
ROE %	79.4%	66.3%	62.5%
ROCE %	100.8%	88.5%	71.0%

Shareholding Pattern

Insiders

71.46%

Institutions

17.77%

Public Float

62.26%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SANOFICONR

No recent headlines available.

SANOFICONR · Healthcare